Bexarotene in the form of Targretin oral capsules is effective alone or in combination therapy for cutaneous T-cell lymphoma.
Investigators from the Department of Dermatology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, United States, studied 70 patients with cutaneous T-cell lymphoma. Patients received oral bexarotene as monotherapy or in combination with other active agents.
An overall response rate of 48 per cent was achieved among the fifty-four patients taking bexarotene as a monotherapy. Because of hypertriglyceridemia, forty-two of these patients (77 percent) also required one or more of the lipid-lowering agents atorvastatin, fenofibrate or gemfibrozil.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!